US3534017A
(en)
|
1967-03-14 |
1970-10-13 |
Kyowa Hakko Kogyo Kk |
Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
|
US4210746A
(en)
|
1978-08-10 |
1980-07-01 |
National Research Development Corporation |
Nucleotide inhibitor of protein synthesis
|
US4285605A
(en)
|
1979-07-02 |
1981-08-25 |
International Business Machines Corporation |
Escapement mechanism and backspace mechanism for a moving paper carriage typewriter having dual pitch capability
|
FR2471785A1
(fr)
|
1979-12-21 |
1981-06-26 |
Fabre Sa Pierre |
Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
|
DE3023787A1
(de)
|
1980-06-25 |
1982-01-21 |
Studiengesellschaft Kohle mbH, 4330 Mülheim |
Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
|
EP0081099A3
(en)
|
1981-12-04 |
1983-08-10 |
Sloan-Kettering Institute For Cancer Research |
Capped oligonucleotide anti-viral agents
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5194428A
(en)
|
1986-05-23 |
1993-03-16 |
Worcester Foundation For Experimental Biology |
Inhibition of influenza virus replication by oligonucleotide phosphorothioates
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
EP0402402B1
(en)
|
1988-02-26 |
1995-12-27 |
Worcester Foundation For Biomedical Research, Inc. |
Inhibition of htlv-iii by exogenous oligonucleotides
|
DE68927417T2
(de)
|
1988-04-27 |
1997-03-20 |
Isis Pharmaceutical Inc |
Oligoribonukleotid-Derivate und ihre Anwendung als antivirale Mittel
|
JP2976436B2
(ja)
|
1988-04-27 |
1999-11-10 |
味の素株式会社 |
新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
|
DE3907562A1
(de)
|
1989-03-09 |
1990-09-13 |
Bayer Ag |
Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
|
EP0472648A4
(en)
|
1989-05-18 |
1992-09-16 |
Microprobe Corporation |
Crosslinking oligonucleotides
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
DK0452457T3
(da)
|
1989-11-03 |
1998-03-02 |
Univ Vanderbilt |
Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
HUT62658A
(en)
|
1990-03-21 |
1993-05-28 |
Isis Pharmaceuticals Inc |
Reagent and process for modifying expression of gene by imitating rna
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
US5166195A
(en)
|
1990-05-11 |
1992-11-24 |
Isis Pharmaceuticals, Inc. |
Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
|
NZ239252A
(en)
|
1990-08-09 |
1997-07-27 |
Genta Inc |
Reagent for attaching a psoralen-containing moiety to an oligonucleotide(derivative); oligonucleotide(derivative)-psoralen conjugates
|
JPH06501843A
(ja)
|
1990-08-14 |
1994-03-03 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
|
US5271941A
(en)
|
1990-11-02 |
1993-12-21 |
Cho Chung Yoon S |
Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
|
DE4110085A1
(de)
|
1991-03-27 |
1992-10-01 |
Boehringer Ingelheim Int |
2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
|
AU661490B2
(en)
|
1991-03-27 |
1995-07-27 |
Research Corporation Technologies, Inc. |
Single-stranded circular oligonucleotides
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
CA2121144C
(en)
|
1991-10-15 |
2001-07-31 |
Phillip Dan Cook |
Oligonucleotides having chiral phosphorus linkages
|
NZ244820A
(en)
|
1991-10-25 |
1994-01-26 |
Isis Pharmaceuticals Inc |
Oligonucleotide inhibitor of epstein-barr virus.
|
US5644048A
(en)
|
1992-01-10 |
1997-07-01 |
Isis Pharmaceuticals, Inc. |
Process for preparing phosphorothioate oligonucleotides
|
WO1993023569A1
(en)
|
1992-05-11 |
1993-11-25 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting viral replication
|
US5606049A
(en)
|
1992-06-03 |
1997-02-25 |
Genta Incorporated |
Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis
|
CA2140428C
(en)
|
1992-07-23 |
2003-07-08 |
Daniel Peter Claude Mcgee |
Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
TW244371B
(sr)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
IL108206A0
(en)
|
1993-01-06 |
1994-04-12 |
Univ Johns Hopkins |
Oligomers having improved stability at acid ph
|
JPH08508714A
(ja)
|
1993-01-25 |
1996-09-17 |
ハイブライドン インコーポレイテッド |
オリゴヌクレオチド・アルキルホスホネートおよびアルキルホスホノチオエート
|
AU6632094A
(en)
|
1993-04-19 |
1994-11-08 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
WO1995003406A2
(en)
|
1993-07-19 |
1995-02-02 |
Gen-Probe Incorporated |
Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
|
JPH0799976A
(ja)
|
1993-09-30 |
1995-04-18 |
Takeda Chem Ind Ltd |
修飾オリゴヌクレオチド
|
US5801235A
(en)
|
1994-05-25 |
1998-09-01 |
Hybridon, Inc. |
Oligonucleotides with anti-cytomegalovirus activity
|
JPH10501224A
(ja)
|
1994-05-27 |
1998-02-03 |
ハイブリドン・インコーポレイテッド |
補体枯渇化および血圧低下のためのオリゴヌクレオチドホスホロチオエートの使用
|
US5866699A
(en)
|
1994-07-18 |
1999-02-02 |
Hybridon, Inc. |
Oligonucleotides with anti-MDR-1 gene activity
|
WO1996007392A2
(en)
|
1994-09-07 |
1996-03-14 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
JPH08154687A
(ja)
|
1994-12-12 |
1996-06-18 |
Yamanouchi Pharmaceut Co Ltd |
アンチセンスオリゴヌクレオチド及び抗ウイルス剤
|
AU4412096A
(en)
|
1994-12-13 |
1996-07-03 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
|
WO1996019572A1
(en)
|
1994-12-22 |
1996-06-27 |
Hybridon, Inc. |
Synthesis of stereospecific oligonucleotide phosphorothioates
|
US6111095A
(en)
|
1995-06-07 |
2000-08-29 |
Merck & Co., Inc. |
Capped synthetic RNA, analogs, and aptamers
|
GB9511720D0
(en)
|
1995-06-09 |
1995-08-02 |
Isis Innovation |
Oligonucleotide phosphorylation method and products
|
US20040234999A1
(en)
|
1996-04-02 |
2004-11-25 |
Farrar Gwenyth Jane |
Genetic suppression and replacement
|
EP1626086A2
(en)
|
1998-04-20 |
2006-02-15 |
Ribozyme Pharmaceuticals, Inc. |
Double-stranded nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
AU751480B2
(en)
|
1998-04-29 |
2002-08-15 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into ribozymes
|
EP1493818A3
(en)
|
1998-04-29 |
2006-02-15 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into ribozymes
|
US6344323B1
(en)
|
1998-09-16 |
2002-02-05 |
Vitagenix, Inc. |
Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
|
CA2403243A1
(en)
|
1999-08-31 |
2001-03-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid based modulators of gene expression
|
EP1220684B2
(en)
|
1999-09-27 |
2010-07-14 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
US20020028784A1
(en)
|
2000-03-10 |
2002-03-07 |
Nest Gary Van |
Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
|
DE10013600A1
(de)
|
2000-03-18 |
2002-01-10 |
Aventis Res & Tech Gmbh & Co |
Reaktive Monomere für die Oligonucleotid- und Polynucleotidsynthese, modifizierte Oligonucleotide und Polynucleotiden und ein Verfahren zu deren Herstellung
|
US6686461B1
(en)
|
2000-03-22 |
2004-02-03 |
Solulink Bioscience, Inc. |
Triphosphate oligonucleotide modification reagents and uses thereof
|
EP1247815A3
(en)
|
2001-03-25 |
2003-01-29 |
Exiqon A/S |
Modified oligonucleotides and uses thereof
|
WO2003008432A1
(en)
|
2001-07-16 |
2003-01-30 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of alpha modified nucleoside triphosphates and compounds therefrom
|
AU2002329667A1
(en)
|
2001-07-30 |
2003-02-17 |
Uta Griesenbach |
Specific inhibition of gene expression by small double stranded rnas
|
FR2832154B1
(fr)
|
2001-11-09 |
2007-03-16 |
Centre Nat Rech Scient |
Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
|
US20030203868A1
(en)
|
2002-02-06 |
2003-10-30 |
Bushman Frederic D. |
Inhibition of pathogen replication by RNA interference
|
IL163688A0
(en)
|
2002-02-28 |
2005-12-18 |
Astrazeneca Ab |
3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents
|
CA2477741A1
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
WO2003078595A2
(en)
|
2002-03-15 |
2003-09-25 |
Astral, Inc. |
Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
|
NZ573064A
(en)
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
MXPA04010282A
(es)
|
2002-04-18 |
2005-08-18 |
Acuity Pharmaceuticals Inc |
Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
|
EP1505152A1
(en)
|
2002-04-26 |
2005-02-09 |
National Institute of Advanced Industrial Science and Technology |
EXPRESSION SYSTEMS FOR STEM LOOP RNA MOLECULE HAVING RNAi EFFECT
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
AU2003256615A1
(en)
|
2002-08-12 |
2004-02-25 |
New England Biolabs, Inc. |
Methods and compositions relating to gene silencing
|
WO2004022777A1
(en)
|
2002-09-04 |
2004-03-18 |
Johnson & Johnson Research Pty Ltd |
METHODS USING dsDNA TO MEDIATE RNA INTERFERENCE (RNAi)
|
ES2359055T3
(es)
|
2002-09-11 |
2011-05-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y el tratamiento de tumores.
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
EP2314691A3
(en)
|
2002-11-14 |
2012-01-18 |
Dharmacon, Inc. |
Fuctional and hyperfunctional siRNA
|
US7696334B1
(en)
|
2002-12-05 |
2010-04-13 |
Rosetta Genomics, Ltd. |
Bioinformatically detectable human herpesvirus 5 regulatory gene
|
US20130130231A1
(en)
|
2002-11-26 |
2013-05-23 |
Isaac Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
EP1998177A3
(en)
|
2003-01-06 |
2009-02-18 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
WO2004074441A2
(en)
|
2003-02-19 |
2004-09-02 |
Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services |
Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto
|
CN1176937C
(zh)
|
2003-02-21 |
2004-11-24 |
复旦大学附属中山医院 |
一种双链rna及其用途
|
US20040261149A1
(en)
|
2003-02-24 |
2004-12-23 |
Fauquet Claude M. |
siRNA-mediated inhibition of gene expression in plant cells
|
AU2004220459B2
(en)
|
2003-03-12 |
2010-08-05 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2004221760B2
(en)
|
2003-03-21 |
2010-03-18 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA (siRNA) analogues
|
WO2004085623A2
(en)
|
2003-03-24 |
2004-10-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
A compact synthetic expression vector comprising double-stranded dna molecules and methods of use thereof
|
US8969543B2
(en)
|
2003-04-03 |
2015-03-03 |
Bioneer Corporation |
SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
|
US20050042641A1
(en)
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
WO2004106517A1
(en)
|
2003-06-03 |
2004-12-09 |
Benitec Australia Limited |
Double-stranded nucleic acid
|
EP1637597A4
(en)
|
2003-06-06 |
2006-07-19 |
Dainippon Sumitomo Pharma Co |
NUCLEIC INFUSION PROCESS
|
CA2528597C
(en)
|
2003-06-11 |
2014-08-05 |
Hybridon, Inc. |
Stabilized immunomodulatory oligonucleotides
|
FR2857013B1
(fr)
|
2003-07-02 |
2005-09-30 |
Commissariat Energie Atomique |
Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
|
WO2005076979A2
(en)
|
2004-02-06 |
2005-08-25 |
Wyeth |
Diagnosis and therapeutics for cancer
|
US20050182005A1
(en)
|
2004-02-13 |
2005-08-18 |
Tuschl Thomas H. |
Anti-microRNA oligonucleotide molecules
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
EP1742958B1
(en)
|
2004-03-15 |
2017-05-17 |
City of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
US20060035815A1
(en)
|
2004-05-04 |
2006-02-16 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
|
MXPA06012605A
(es)
|
2004-05-04 |
2006-12-15 |
Nastech Pharm Co |
Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
|
EP1745131A2
(en)
|
2004-05-12 |
2007-01-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
METHOD TO INDUCE RNAi IN PROKARYOTIC ORGANISMS
|
JPWO2006016574A1
(ja)
|
2004-08-12 |
2008-05-01 |
国立大学法人 熊本大学 |
RNAiを利用した抗腫瘍剤
|
ATE505540T1
(de)
|
2004-11-16 |
2011-04-15 |
Qiagen Gmbh |
Genabschaltung (gene silencing) durch hybride sens-dna und antisens-rna konstrukte, gekoppelt an ein peptid zur erleichterten aufnahme in zellen
|
WO2006063252A2
(en)
|
2004-12-09 |
2006-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
|
CA2593238C
(en)
|
2005-01-07 |
2014-11-18 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method to trigger rna interference
|
US20100015041A1
(en)
|
2005-01-18 |
2010-01-21 |
Caltagirone Gaetano T |
Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof
|
US20060178334A1
(en)
|
2005-02-04 |
2006-08-10 |
City Of Hope |
Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
|
JP4972538B2
(ja)
|
2005-02-07 |
2012-07-11 |
武田薬品工業株式会社 |
神経変性疾患の予防・治療剤
|
JP4645234B2
(ja)
|
2005-03-03 |
2011-03-09 |
和光純薬工業株式会社 |
架橋剤、それを用いた架橋方法、遺伝子発現調節方法および遺伝子機能調査方法
|
DK1866414T3
(da)
|
2005-03-31 |
2012-04-23 |
Calando Pharmaceuticals Inc |
Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
|
US7893244B2
(en)
|
2005-04-12 |
2011-02-22 |
Intradigm Corporation |
Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
|
BRPI0610499A2
(pt)
|
2005-04-12 |
2010-06-22 |
Intradigm Corp |
moléculas de ácido nucléico , composições e usos das referidas moléculas
|
US20070066521A1
(en)
|
2005-04-13 |
2007-03-22 |
Fauquet Claude M |
Short RNA-binding proteins
|
WO2006119643A1
(en)
|
2005-05-12 |
2006-11-16 |
Replicor Inc. |
Anti-ocular angiogenesis molecules and their uses
|
WO2006122409A1
(en)
|
2005-05-16 |
2006-11-23 |
Replicor Inc. |
Antimicrobial molecules and their uses
|
DK1888749T3
(en)
|
2005-06-01 |
2015-01-05 |
Polyplus Transfection |
Oligonucleotides for RNA interference and their biological applications
|
WO2006130949A1
(en)
|
2005-06-08 |
2006-12-14 |
Replicor Inc. |
Anti amyloid-related disease molecules and their uses
|
WO2007007317A1
(en)
|
2005-07-07 |
2007-01-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Nucleic acid agents for downregulating h19, and methods of using same
|
EP1915449B1
(en)
|
2005-08-17 |
2016-03-23 |
Bioneer Corporation |
Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
|
EP1934359A2
(en)
|
2005-09-08 |
2008-06-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
|
EP1764108A1
(en)
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
WO2007031322A1
(en)
|
2005-09-14 |
2007-03-22 |
Gunther Hartmann |
Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
|
EP1764107A1
(en)
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
WO2007038788A2
(en)
|
2005-09-29 |
2007-04-05 |
The Cleveland Clinic Foundation |
Small interfering rnas as non-specific drugs
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
EP2431467A3
(en)
|
2005-11-17 |
2012-05-02 |
Board Of Regents, The University Of Texas |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
CA2634046A1
(en)
|
2005-12-12 |
2007-06-21 |
The University Of North Carolina At Chapel Hill |
Micrornas that regulate muscle cell proliferation and differentiation
|
US8058252B2
(en)
|
2005-12-30 |
2011-11-15 |
Institut Gustave Roussy |
Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors
|
EP2004141A2
(en)
|
2006-03-17 |
2008-12-24 |
Novosom AG |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
JP5761911B2
(ja)
|
2006-04-07 |
2015-08-12 |
イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. |
Tlr7およびtlr8に対する安定化免疫調節rna(simra)化合物
|
US20080091005A1
(en)
|
2006-07-20 |
2008-04-17 |
Visigen Biotechnologies, Inc. |
Modified nucleotides, methods for making and using same
|
EP4082551A1
(en)
|
2006-08-08 |
2022-11-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
JP5407862B2
(ja)
|
2006-10-04 |
2014-02-05 |
サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク(セーエヌエールエス) |
siRNAおよび脂質性4,5−二置換2−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
|
EP2338499A1
(en)
|
2006-10-10 |
2011-06-29 |
Gunther Hartmann |
5' triphosphate oligonucleotide induces anti-viral response
|
WO2008045576A2
(en)
|
2006-10-12 |
2008-04-17 |
Yijia Liu |
Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
|
CN101190944A
(zh)
|
2006-12-01 |
2008-06-04 |
北京诺赛基因组研究中心有限公司 |
人类新细胞因子及其用途
|
WO2008080091A2
(en)
|
2006-12-21 |
2008-07-03 |
Vical Incorporated |
Activation of rig-i pathway
|
JP2010512786A
(ja)
|
2006-12-21 |
2010-04-30 |
イントラダイム コーポレイション |
ガンを処置するための抑制性ポリヌクレオチドの組成物および方法
|
US7858772B2
(en)
*
|
2006-12-22 |
2010-12-28 |
Roche Molecular Systems, Inc. |
Compounds and methods for synthesis and purification of oligonucleotides
|
EP2111450A2
(en)
|
2007-01-16 |
2009-10-28 |
Yissum Research Development Company of the Hebrew University of Jerusalem |
Nucleic acid constructs and methods for specific silencing of h19
|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
WO2008099396A1
(en)
|
2007-02-15 |
2008-08-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Use of h19-silencing nucleic acid agents for treating restenosis
|
EP2113565A4
(en)
|
2007-02-19 |
2010-08-18 |
Univ Kyoto |
CONDUCTIVE SUBSTRATE FOR NUCLEIC ACID RELIEF AND NUCLEIC ACID RELIEF PROCESS
|
MY173854A
(en)
|
2007-03-13 |
2020-02-25 |
Malaysian Palm Oil Board |
Expression regulatory elements
|
US20090226525A1
(en)
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
CN101088565A
(zh)
|
2007-04-17 |
2007-12-19 |
华东师范大学 |
miRNA-34a的用途
|
CN101289486B
(zh)
*
|
2007-04-18 |
2012-05-30 |
上海吉凯基因化学技术有限公司 |
一种合成rna单体的方法
|
WO2008134593A1
(en)
|
2007-04-25 |
2008-11-06 |
President And Fellows Of Harvard College |
Molecular circuits
|
AU2007352163A1
(en)
|
2007-05-01 |
2008-11-06 |
Ercole Biotech, Inc. |
Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease
|
US9109012B2
(en)
|
2007-05-29 |
2015-08-18 |
Nature Technology Corporation |
Vectors and method for genetic immunization
|
KR20100063048A
(ko)
|
2007-07-31 |
2010-06-10 |
더 존스 홉킨스 유니버시티 |
신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20110082185A1
(en)
|
2007-09-17 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Cancer-testis gene silencing agents and uses thereof
|
JP2011500005A
(ja)
|
2007-10-11 |
2011-01-06 |
ユニバーシティー ヘルス ネットワーク |
ヒト造血幹細胞の生着を増加させるためのSIRPα−CD47相互作用の調節およびそのための化合物
|
CA2702039A1
(en)
|
2007-10-12 |
2009-04-23 |
Intradigm Corporation |
Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
|
DE102007052114B4
(de)
|
2007-10-30 |
2011-01-05 |
T2Cure Gmbh |
Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
|
AU2008324068A1
(en)
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
JP5753382B2
(ja)
*
|
2007-11-06 |
2015-07-22 |
アディウティーダ ファーマシューティカルズ ゲーエムベーハー |
修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
|
US8735567B2
(en)
|
2007-11-06 |
2014-05-27 |
Patrick Y. Lu |
Multi-targeted RNAi therapeutics for scarless wound healing of skin
|
US8575121B2
(en)
|
2007-11-12 |
2013-11-05 |
The United States of America as represented by the Secetary of the Department of Health and Human Services |
Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
|
PT2492355E
(pt)
|
2007-11-29 |
2015-09-10 |
Molecular Health Gmbh |
Recetor de eritropoietina protetora de tecido (nepor) e métodos de utilização
|
US8357501B2
(en)
|
2007-11-29 |
2013-01-22 |
Molecular Health Gmbh |
Tissue protective erythropoietin receptor (NEPOR) and methods of use
|
GB0725321D0
(en)
|
2007-12-31 |
2008-02-06 |
Syntaxin Ltd |
Delivery vehicles
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
EP3045536B1
(en)
|
2008-05-21 |
2019-07-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
WO2009151600A2
(en)
|
2008-06-10 |
2009-12-17 |
Tufts University |
Smad proteins control drosha-mediated mirna maturation
|
CN101632833B
(zh)
|
2008-07-25 |
2013-11-06 |
上海市计划生育科学研究所 |
一种前列腺癌相关的基因及其用途
|
WO2010028079A2
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Pharmaceuticals, Inc |
Synthetic methods and derivatives of triphosphate oligonucleotides
|
WO2011028218A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
WO2010042755A2
(en)
|
2008-10-08 |
2010-04-15 |
Chimeros Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
WO2010042751A2
(en)
|
2008-10-08 |
2010-04-15 |
Chimeros Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
WO2010042749A2
(en)
|
2008-10-08 |
2010-04-15 |
Chimeros Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
WO2010042742A2
(en)
|
2008-10-08 |
2010-04-15 |
Chimeros Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
JP4936343B6
(ja)
|
2008-10-23 |
2018-06-27 |
国立大学法人 東京大学 |
microRNAの機能阻害法
|
WO2010062502A1
(en)
|
2008-11-03 |
2010-06-03 |
University Of Utah Research Foundation |
Carriers for the delivery of nucleic acids to cells and methods of use thereof
|
CA2753562A1
(en)
|
2009-02-26 |
2010-09-02 |
The Ohio State University Research Foundation |
Micrornas in never-smokers and related materials and methods
|
US8987222B2
(en)
|
2009-04-08 |
2015-03-24 |
University Of Massachusetts |
Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US20100323018A1
(en)
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
EP2277508B1
(en)
|
2009-07-09 |
2012-04-25 |
Marina Biotech, Inc. |
Emulation of lipoprotein structures
|
US9238811B2
(en)
|
2009-07-14 |
2016-01-19 |
Northeastern University |
siRNA phospholipid conjugate
|
CA2768851A1
(en)
|
2009-07-23 |
2011-01-27 |
The Trustees Of Princeton University |
Inhibitors of mtor kinase as anti-viral agents
|
EP2327783A1
(en)
|
2009-11-27 |
2011-06-01 |
Universitätsklinikum Freiburg |
Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
|
DE202009015670U1
(de)
|
2009-11-30 |
2011-04-14 |
Mcairlaid's Vliesstoffe Gmbh & Co. Kg |
Absorptionskörper zur Auflage auf Wunden
|
US20110247091A1
(en)
|
2010-03-26 |
2011-10-06 |
The Governors Of The University Of Alberta |
Transgenic Cells and Chickens Expressing RIG-I
|
WO2011133559A2
(en)
|
2010-04-19 |
2011-10-27 |
University Of Georgia Research Foundation, Inc. |
Alpha tubulin acetyltransferase
|
EP2385120A1
(en)
|
2010-05-04 |
2011-11-09 |
Justus-Liebig- Universitat Giessen |
Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension
|
WO2011140285A2
(en)
|
2010-05-04 |
2011-11-10 |
Sirnaomics, Inc. |
Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
|
CN101974529B
(zh)
|
2010-09-21 |
2013-04-03 |
南京大学(苏州)高新技术研究院 |
含自由三磷酸基团的TGF-β特异性siRNA及其应用
|
WO2012056440A1
(en)
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
WO2012056441A1
(en)
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
Compositions and methods for specific cleavage of exogenous rna in a cell
|
CN102475892A
(zh)
|
2010-11-22 |
2012-05-30 |
大连创达技术交易市场有限公司 |
作为制备抗癌药物的反义miRNA-210的用途
|
JP5836394B2
(ja)
|
2010-12-30 |
2015-12-24 |
サムヤン バイオファーマシューティカルズ コーポレイション |
陽イオン性脂質を含む陰イオン性薬物伝達体およびその製造方法
|
US8461224B2
(en)
|
2011-03-04 |
2013-06-11 |
National Health Research Institutes |
Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
|
WO2012125987A2
(en)
|
2011-03-17 |
2012-09-20 |
Massachusetts Institute Of Technology |
Delivery system
|
EP2508530A1
(en)
*
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
JP2014520506A
(ja)
|
2011-07-04 |
2014-08-25 |
コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション |
核酸複合体
|
EP2551354A1
(en)
|
2011-07-25 |
2013-01-30 |
Universität Heidelberg |
Functionalization of RNA oligonucleotides
|
US20130189367A1
(en)
|
2011-07-29 |
2013-07-25 |
University Of Washington Through Its Center For Commercialization |
Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells
|
WO2013020986A1
(de)
|
2011-08-08 |
2013-02-14 |
Universität Regensburg |
Polyanion-nanokomplexe für therapeutische anwendungen
|
EP2765983A1
(de)
|
2011-10-11 |
2014-08-20 |
Hans Kosak |
Zusammensetzung zur einbringung von nukleinsäuren in zellen
|
WO2013053481A1
(de)
|
2011-10-11 |
2013-04-18 |
Secutech International Pte. Ltd. |
Dimethylsulfoxid als lösungsmittel für nukleinsäuren
|
AU2012340094A1
(en)
|
2011-11-17 |
2014-05-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Auto -recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
|
JP2015518475A
(ja)
|
2012-04-10 |
2015-07-02 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) |
非アルコール性脂肪性肝炎の治療方法
|
US20130302252A1
(en)
|
2012-05-11 |
2013-11-14 |
University Of Washington Through Its Center For Commercialization |
Polyarginine-coated magnetic nanovector and methods of use thereof
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
US20140287023A1
(en)
|
2013-02-11 |
2014-09-25 |
Mcgill University |
5'-triphosphate oligoribonucleotides
|